Axsome Therapeutics Inc

NASDAQ:AXSM   3:59:56 PM EDT
57.14
+2.75 (+5.06%)
Regulatory, Earnings Announcements

Axsome Therapeutics Announces Positive Efficacy And Safety Results From Phase 3 Comet Long-Term Trial And Comet-Au Trial Of Axs-05 In Major Depressive Disorder

Published: 12/01/2020 12:06 GMT
Axsome Therapeutics Inc (AXSM) - Axsome Therapeutics Announces Positive Efficacy and Safety Results From Phase 3 Comet Long-term Trial and Comet-au Trial of Axs-05 in Major Depressive Disorder.
Axsome Therapeutics Inc - NDA on Track for Submission in January 2021.
Axsome Therapeutics - Rapidand Substantial Improvement in Depressive Symptoms Achieved by 40% of Patients at 2 Weeks, 73% at 6 Weeks, Sustained Over 12 Months.
Axsome Therapeutics - Rapid and Substantial Improvement in Functioning Achieved by 55% of Patients at 2 Weeks, 71% at 6 Weeks, Sustained Over 12 Months.
Axsome Therapeutics - Marked Or Moderate Improvement in Depression Achieved by 50% of Patients at 2 Weeks, 83% at 6 Weeks, Sustained Over 12 Months.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.95

Next Quarter Revenue Guidance is expected to be $0.44 Million
Next Quarter EPS Guidance is expected to be -$1.10

More details on our Analysts Page.